



**Continuous glucose monitoring in pregnant women with type 1 diabetes
an observational cohort study of 186 pregnancies**

Kristensen, Karl; Ögge, Linda E.; Sengpiel, Verena; Kjölhede, Karin; Dotevall, Annika; Elfvin, Anders; Knop, Filip K.; Wiberg, Nana; Katsarou, Anastasia; Shaat, Nael; Kristensen, Lars; Berntorp, Kerstin

Published in:
Diabetologia

DOI:
[10.1007/s00125-019-4850-0](https://doi.org/10.1007/s00125-019-4850-0)

Publication date:
2019

Document version
Publisher's PDF, also known as Version of record

Citation for published version (APA):
Kristensen, K., Ögge, L. E., Sengpiel, V., Kjölhede, K., Dotevall, A., Elfvin, A., Knop, F. K., Wiberg, N., Katsarou, A., Shaat, N., Kristensen, L., & Berntorp, K. (2019). Continuous glucose monitoring in pregnant women with type 1 diabetes: an observational cohort study of 186 pregnancies. *Diabetologia*, 62(7), 1143-1153.
<https://doi.org/10.1007/s00125-019-4850-0>



Continuous glucose monitoring in pregnant women with type 1 diabetes: an observational cohort study of 186 pregnancies

Karl Kristensen^{1,2,3} · Linda E. Ögge^{4,5} · Verena Sengpiel^{4,5} · Karin Kjölhede^{4,5} · Annika Dotevall^{5,6} · Anders Elfvin^{5,7} · Filip K. Knop^{8,9} · Nana Wiberg^{1,3} · Anastasia Katsarou^{10,11} · Nael Shaat^{10,11} · Lars Kristensen² · Kerstin Berntorp^{10,11}

Received: 16 December 2018 / Accepted: 25 February 2019 / Published online: 23 March 2019
© The Author(s) 2019

Abstract

Aims/hypothesis The aim of this study was to analyse patterns of continuous glucose monitoring (CGM) data for associations with large for gestational age (LGA) infants and an adverse neonatal composite outcome (NCO) in pregnancies in women with type 1 diabetes.

Methods This was an observational cohort study of 186 pregnant women with type 1 diabetes in Sweden. The interstitial glucose readings from 92 real-time (rt) CGM and 94 intermittently viewed (i) CGM devices were used to calculate mean glucose, SD, CV%, time spent in target range (3.5–7.8 mmol/l), mean amplitude of glucose excursions and also high and low blood glucose indices (HBGI and LBGI, respectively). Electronic records provided information on maternal demographics and neonatal outcomes. Associations between CGM indices and neonatal outcomes were analysed by stepwise logistic regression analysis adjusted for confounders.

Results The number of infants born LGA was similar in rtCGM and iCGM users (52% vs 53%). In the combined group, elevated mean glucose levels in the second and the third trimester were significantly associated with LGA (OR 1.53, 95% CI 1.12, 2.08, and OR 1.57, 95% CI 1.12, 2.19, respectively). Furthermore, a high percentage of time in target in the second and the third trimester was associated with lower risk of LGA (OR 0.96, 95% CI 0.94, 0.99 and OR 0.97, 95% CI 0.95, 1.00, respectively). The same associations were found for mean glucose and for time in target and the risk of NCO in all trimesters. SD was significantly associated with LGA in the second trimester and with NCO in the third trimester. Glucose patterns did not differ between rtCGM and iCGM users except that rtCGM users had lower LBGI and spent less time below target.

Conclusions/interpretation Higher mean glucose levels, higher SD and less time in target range were associated with increased risk of LGA and NCO. Despite the use of CGM throughout pregnancy, the day-to-day glucose control was not optimal and the incidence of LGA remained high.

Keywords Continuous glucose monitoring · Fetal growth · Neonatal complications · Pregnancy · Type 1 diabetes

Electronic supplementary material The online version of this article (<https://doi.org/10.1007/s00125-019-4850-0>) contains peer-reviewed but unedited supplementary material, which is available to authorised users.

✉ Karl Kristensen
karl.kristensen@med.lu.se

¹ Department of Clinical Sciences Lund, Lund University, Sölvegatan 19, 221 84 Lund, Sweden

² The Parker Institute, Copenhagen University Hospital, Copenhagen, Denmark

³ Department of Obstetrics and Gynecology, Skåne University Hospital, Malmö, Sweden

⁴ Department of Obstetrics and Gynecology, Sahlgrenska University Hospital, Gothenburg, Sweden

⁵ Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden

⁶ Department of Medicine, Östra/Sahlgrenska University Hospital, Gothenburg, Sweden

⁷ Department of Pediatrics, Sahlgrenska University Hospital, Gothenburg, Sweden

⁸ Clinical Metabolic Physiology, Steno Diabetes Center Copenhagen, Gentofte Hospital, Hellerup, Denmark

⁹ Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

¹⁰ Department of Endocrinology, Skåne University Hospital, Malmö, Sweden

¹¹ Department of Clinical Sciences Malmö, Lund University, Lund, Sweden

Research in context

What is already known about this subject?

- Pregnancy in women with type 1 diabetes is associated with increased risk of neonatal complications and delivery of a large for gestational age (LGA) infant
- Fetal exposure to maternal hyperglycaemia is considered the major determinant of fetal overgrowth
- Continuous glucose monitoring (CGM) can increase the time that blood glucose is in the target range and reduce neonatal complications

What is the key question?

- To what extent are CGM-derived measures of glucose control associated with LGA and a neonatal composite outcome (NCO) in pregnancies in women with type 1 diabetes in a real-world setting?

What are the new findings?

- Despite the use of CGM throughout pregnancy, the day-to-day glucose control was not optimal and the incidence of LGA was high (53%)
- Higher mean glucose levels, increased glucose variability and less time in target range were associated with LGA and NCO
- Outcomes were comparable in women monitored by intermittently viewed CGM and real-time CGM

How might this impact on clinical practice in the foreseeable future?

- The results suggest that increased technical support from the diabetes team and an intensified focus on keeping blood glucose in the target range throughout pregnancy would reduce the risk of adverse neonatal outcome

Abbreviations

CGM	Continuous glucose monitoring
HBGI	High blood glucose index
iCGM	Intermittently viewed CGM
LBGI	Low blood glucose index
LGA	Large for gestational age
MAGE	Mean amplitude of glucose excursions
NCO	Neonatal composite outcome
NICU	Neonatal intensive care unit
rtCGM	Real-time CGM

Introduction

Despite improved glycaemic control, the prevalence of macrosomia and large for gestational age (LGA) remains high in babies born to women with type 1 diabetes, affecting approximately one-half of these newborn infants [1–3]. In addition to an increased risk of obstetric and neonatal adverse outcomes [4], LGA infants have an increased risk of developing obesity, diabetes and cardiovascular disease in later life [5–8].

Fetal exposure to maternal hyperglycaemia is thought to be the major determinant of fetal overgrowth in pregnancies in women with type 1 diabetes [9]. Thus, the overarching goal of prenatal care in these women is to achieve near normal

glycaemic control, usually estimated by self-monitoring of plasma glucose and HbA_{1c}. However, HbA_{1c} may not adequately reflect fetal glycaemic exposure as it represents an average measure of glycaemic control in the preceding 2–3 months and does not capture acute glucose fluctuations or intra- and inter-day glycaemic variability [10–12]. Moreover, tight glycaemic control may be difficult to accomplish, given the complexity of insulin dose adjustment required to account for gestational changes in insulin sensitivity and variability in insulin absorption during pregnancy [13, 14]. Recent data have shown that fewer than 50% of pregnant women with diabetes in the UK reach target HbA_{1c} levels [15].

Continuous glucose monitoring (CGM) technology provides unique insights into daily glycaemic control and permits a better understanding of how glycaemic patterns and glucose variability may influence pregnancy outcomes. The effectiveness of intermittent use of CGM in pregestational diabetes (type 1 diabetes and type 2 diabetes) in improving glycaemic control and reducing the risk of macrosomia has been evaluated in two randomised controlled trials, in the UK and Denmark, with conflicting results [16, 17]. Merged data from the two studies showed that LGA was associated with trimester-specific differences in daily glucose patterns, i.e. with lower mean glucose and less glycaemic variability in the first trimester and with higher mean glucose and more variable glucose levels in the second and third trimesters

[18]. Other groups have similarly shown that higher glycaemic variability, especially during late pregnancy, may increase the risk of LGA [19, 20]. A more recent trial, CONCEPTT, found that continuous use of real-time CGM in pregnancies in women with type 1 diabetes resulted in greater reduction in HbA_{1c}, more time spent in the target range, less time spent above the target range and reduced glucose variability. Furthermore, neonatal outcomes were improved, including a lower incidence of LGA infants and a decrease in neonatal hypoglycaemia [21]. The extent to which the CGM-derived measures of glucose control are associated with LGA in a clinical setting is, however, unclear.

In our regions in southwestern Sweden, women with type 1 diabetes are offered a CGM device as part of routine pregnancy care. Here, we report CGM summary data from a cohort of Swedish women who received pregnancy care during the years 2014 to 2017, using the recently published international consensus recommendation for optimal analysis of CGM data [22]. The aim of the study was to determine patterns of maternal glucose control during different phases of pregnancy and to examine whether these patterns are associated with LGA and a predefined adverse neonatal composite outcome (NCO).

Methods

Study population We performed a retrospective analysis of CGM data in women with type 1 diabetes who received pregnancy care between 2014 and 2017 at two large tertiary care antenatal clinics in Sweden (Skåne University Hospital and Östra/Sahlgrenska University Hospital). All women above 18 years of age using a CGM device compatible with the internet-based Diasend system (Glooko, Gothenburg, Sweden) were eligible for inclusion in the study. CGM data were available from 192 women. Of these, three women decided to opt out. Another three women were excluded because of: termination of pregnancy due to chromosome aberration ($n = 1$); intrauterine fetal demise ($n = 1$); and multiple gestation ($n = 1$). After exclusion of these pregnancies, CGM data from 186 singleton pregnancies were available for analysis.

Management of diabetes in pregnancy All women received routine clinical care, with antenatal visits every 2 to 4 weeks. In Sweden, the use of CGM is reimbursed in type 1 diabetes outside of pregnancy if adequate glucose control is not achieved by conventional methods, and for all women in pregnancy. Women who were not already using a CGM device before pregnancy ($n = 84$) were offered one at the first antenatal clinic visit, either real-time (rt) CGM or intermittently viewed (i) CGM ($n = 102$). The women made their own choice of which CGM device to use. In all, 40 women declined or did not get along with CGM throughout pregnancy.

Moreover, 45 women used CGM devices or pumps not compatible with the Diasend system (Medtronic). In addition to CGM, self-monitored plasma glucose measurements were recommended at a minimum frequency of twice daily. Treatment goals for glucose were <6 mmol/l before meals, <8 mmol/l 1 h after meals and 6–8 mmol/l before bedtime. All glucose values were downloaded to the Diasend system on a weekly basis and the results were communicated to a diabetologist or a trained diabetes nurse for adjustment of insulin doses. HbA_{1c} was measured every 4 to 8 weeks during pregnancy and the mean value for each trimester was calculated. HbA_{1c} analysis was performed according to the International Federation of Clinical Chemistry standards, with measurement in mmol/mol and conversion to % levels according to the National Glycohemoglobin Standardization Program for dual reporting.

CGM system The CGM device used was either Dexcom G4 (Dexcom, San Diego, CA, USA) or Freestyle Libre (Abbott Diabetes Care, Alameda, CA, USA), which are both compatible with the Diasend system. The Dexcom G4 system, hereon referred to as rtCGM, measures subcutaneous interstitial glucose concentration every 10 s and generates a glucose value every 5 min (with 288 recordings per day). The monitor requires calibration by the user against capillary plasma glucose twice a day. The Freestyle Libre system, hereon referred to as iCGM, uses a similar method to show continuous glucose measurements retrospectively at the time of checking. It uploads the glucose level every 60 s and generates a glucose value every 15 min (with 96 recordings per day). The device requires no calibration by the user. An important difference between the two systems is that rtCGM has an alarm that warns the user if the glucose is trending towards hypoglycaemia or hyperglycaemia. In all, 38% of iCGM users were CGM naive as opposed to 72% of rtCGM users.

CGM data management The raw downloaded CGM dataset was stratified for gestational day and week using Microsoft Access software (Microsoft 2015, Redmond, WA, USA). The dataset for each pregnancy was split into 14-day periods and trimesters (gestational weeks <13 , 13–28 and >28). We followed the recently published consensus on use of CGM and required that there were a minimum of 14 consecutive days of data with at least 80% coverage for inclusion [22].

CGM metrics We calculated a range of summary statistical CGM indices from the raw downloaded glucose data, including mean CGM glucose level and the percentage of time spent within, below and above the pregnancy glucose target range (3.5–7.8 mmol/l). Measures of glycaemic variability included the following: SD of mean glucose; CV%; mean amplitude of glucose excursions (MAGE), which summarises glycaemic variability by identifying and summarising significant glucose

peaks and nadirs for which amplitude exceeds one SD [23]; high blood glucose index (HBGI) and low blood glucose index (LBGI), which convert glucose values into risk scores around zero—predicting the risk of high and low glucose values, respectively [24]. For the calculation of MAGE, we used the algorithm described by Baghurst [25] but did not include amplitudes if the missing values exceeded 60 min [26]. The HBGI and LBGI are derived from a logarithmic transformation of the blood glucose scale that balances the amplitude of hypoglycaemic and hyperglycaemic ranges (enlarging the former and shrinking the latter) and makes the transformed data symmetric around zero—fitting a normal distribution [24]. For the calculation of HBGI and LBGI, we used the formulae described by Fabris et al [27].

Obstetric data and outcomes Electronic antenatal and perinatal records provided data on maternal age, parity, BMI, country of origin, HbA_{1c} levels, duration of diabetes, insulin regimen (i.e. insulin pump or multiple daily injections), mode of delivery, birthweight, gestational age at birth and sex of infant. In addition, information about pre-eclampsia or pregnancy-induced hypertension was obtained. All pregnancies were dated by ultrasound examination before 22 weeks of gestation. LGA was defined as birthweight >2 SD above the expected birthweight for gestational age and sex, respectively, according to the Swedish reference curve for fetal growth [28]. Macrosomia was defined as birthweight >4500 g. Neonatal complications, such as macrosomia, shoulder dystocia, neonatal hypoglycaemia (defined as plasma glucose <2.6 mmol/l >3 h after birth) or admission to the neonatal intensive care unit (NICU) for more than 24 h, were recorded. The main neonatal outcomes were LGA, and NCO that included at least one of: macrosomia; shoulder dystocia; neonatal hypoglycaemia; or admission to NICU for more than 24 h.

Ethical considerations The study was approved by the Ethics Committee of Lund University (2017/322) and was conducted in accordance with the Swedish Act on Ethics Review of Research Involving Humans and the Swedish Act on Personal Data. All women who were included received written information about the study and gave informed consent.

Statistics Differences in means were tested with unpaired *t* test and differences in medians were tested with the Mann–Whitney *U* test. Frequencies were compared using the χ^2 test. The (fixed) effect(s) of gestational age were analysed by repeated-measures mixed-model analysis (linear, compound symmetry). Differences in glucose outcome(s) between women monitored by either rtCGM or iCGM were analysed by one-way repeated-measures ANOVA. Associations between the glucose indices and neonatal outcomes were analysed by stepwise (hierarchical) logistical regression analysis with and without adjusting for confounders. The regression model was adjusted for maternal

age, smoking, early-pregnancy BMI, and CGM device. The regression models were not adjusted for the intermediate variables HbA_{1c}, gestational age or maternal gestational weight gain [29]. Preterm deliveries before 34 weeks were excluded from the model testing for associations with the NCO. Missing data were below 5% for all variables. Two-sided *p* values <0.05 were considered to be statistically significant. IBM SPSS Statistics version 24.0 for Windows (IBM Corporation, Armonk, NY, USA) was used for all analyses. Based on the size of the cohort and the volume of CGM data available, our analyses had 80% power at the 5% level to detect a 0.4 mmol/l difference in mean glucose concentration between participants who delivered infants with or without LGA.

Results

Measurements in analysis Data from the 186 singleton pregnancies (105 from Skåne University Hospital and 81 from Östra/Sahlgrenska University Hospital) with at least one 2-week episode with 80% coverage were available for analysis. Altogether, the dataset comprised 2944 2-week episodes. After the exclusion of 638 2-week episodes with less than 80% coverage, 5.75 million glucose measurements conducted over 2306 separate measurement episodes were available for the analysis. The excluded CGM profiles (32% rtCGM and 12% iCGM) were evenly spread across trimesters. Of the 186 women, 155 (83%) had measurement episodes in the first trimester, 165 (89%) in the second trimester and 167 (90%) in the third trimester. Electronic supplementary material (ESM) Table 1 shows the number of women and the number of measurements made in the total cohort according to the glucose monitoring system used.

rtCGM vs iCGM Mean (SD) values of all the calculated glucose indices for women monitored by either rtCGM or iCGM are shown in ESM Table 2. Figure 1 (a–c) illustrates changes in the proportion of time spent in euglycaemia, hyperglycaemia and hypoglycaemia throughout gestation in the respective CGM group. There were no trimester-specific differences in the proportions of time spent in euglycaemia ($p = 0.54$ – 0.65) or in hyperglycaemia ($p = 0.12$ – 0.18). However, women monitored by rtCGM spent less time in hypoglycaemia compared with iCGM users ($p = 0.006$ in the first trimester and $p = 0.004$ in the second and third trimesters). Likewise, the LBGI was significantly lower in all trimesters in women monitored by rtCGM ($p < 0.001$). There were no significant differences for mean glucose levels, SD, CV%, MAGE or HBGI between the two groups (ESM Table 2). There was a clear trend of improved glucose control with increasing gestational age for all the glucose indices in the combined group of women monitored by either rtCGM or iCGM ($p < 0.001$, fixed effect, linear mixed model).

As our intention was to evaluate data pooled from the two CGM systems, we analysed differences in clinical characteristics and outcomes between women using rtCGM and women using iCGM. As shown in Table 1, the maternal characteristics were comparable, with two exceptions. Insulin pumps were used more commonly by women with rtCGM (42% as opposed to 16%). Users of rtCGM also had a longer duration of diabetes. Mean HbA_{1c} levels during pregnancy (52 mmol/mol [6.9%] in the first trimester, and 45 mmol/mol [6.3%] in the second and third trimesters) indicated that overall the women had acceptable glucose control. The proportion of women who achieved a target HbA_{1c} level of <48 mmol/mol (6.5%) in early pregnancy was 37% and this increased to 71% and 68% in the second and third trimesters, respectively, with no significant difference between women using rtCGM and iCGM.

As shown in Table 2, there was no significant difference in maternal and neonatal outcomes between women using rtCGM and women using iCGM. The median gestational age at delivery was 38 weeks with a Caesarean section rate of 47% and an LGA rate of 53%. The proportion of women with LGA offspring did not differ between the two sites of inclusion ($p = 0.8$).

Glycaemic measures in relation to outcomes Glycaemic measures recorded and calculated separately for the total cohort and for women who delivered LGA infants and women who delivered non-LGA infants in each trimester are presented in Table 3. Overall, the mean glucose level, SD, CV%, percentage time in hyperglycaemia, MAGE and HBGI decreased in each trimester, whereas the time spent in target increased. This improvement in glucose control was not reflected in HbA_{1c} levels in the latter part of pregnancy. However, the occurrence of LGA was significantly associated with the HbA_{1c} levels in all trimesters. The mean glucose levels and the percentage time spent below, in and above the target range were significantly associated with LGA in the second and third trimesters. Furthermore, LGA was associated with a significantly higher SD of mean glucose in the second trimester.

To avoid major confounding from prematurity, we included the women with late preterm and term pregnancy in the regression analysis testing for associations with the NCO. Eight women with preterm delivery <34 weeks were excluded from the analysis. Before and after adjusting for confounders, the mean glucose levels and the percentage time spent below, in and above the target range were significantly associated with the occurrence of short-term neonatal complications in all trimesters, as was the SD of mean glucose in the third trimester (ESM Table 3).

As indicated in Table 3 and ESM Table 3, the LBGI values in the second and third trimesters were inversely associated with LGA ($p = 0.01$ and $p < 0.01$, respectively) and NCO ($p < 0.01$ and $p < 0.01$, respectively). Changes in mean glucose levels over gestation in relation to outcomes (LGA and NCO)




Fig. 1 Mean \pm SEM of time (%) in (a), above (b) and below (c) the target glucose range (3.5–7.8 mmol/l) in women with type 1 diabetes monitored by rtCGM (white) and iCGM (black) during pregnancy

Table 1 Maternal characteristics according to glucose monitoring system

Characteristic	Total (n = 186)	rtCGM (n = 92)	iCGM (n = 94)	p value
Age, years	31 (19–44)	31 (19–41)	31 (21–44)	0.90
Smokers	21 (11)	8 (9)	13 (14)	0.27
European descent	170 (91)	85 (92)	85 (90)	0.80
Diabetes duration, years	15 (1–34)	17 (2–32)	14 (1–34)	<0.05
Insulin pump	54 (29)	39 (42)	15 (16)	<0.001
Primipara	88 (47)	45 (49)	43 (46)	0.67
Early-pregnancy BMI, kg/m ²	25.9 ± 4.7	26.4 ± 4.8	25.3 ± 4.5	0.09
Gestational weight gain, kg	14.3 ± 5.5	14.9 ± 6.6	13.8 ± 4.2	0.17
HbA _{1c}				
Trimester 1, mmol/mol (%)	52.4 ± 10.5 (6.9 ± 1.0)	52.5 ± 11.1 (7.0 ± 1.0)	52.3 ± 9.8 (6.9 ± 0.9)	0.90
Trimester 2, mmol/mol (%)	45.2 ± 7.9 (6.3 ± 0.7)	45.0 ± 7.6 (6.3 ± 0.7)	45.3 ± 8.3 (6.3 ± 0.8)	0.83
Trimester 3, mmol/mol (%)	45.7 ± 7.6 (6.3 ± 0.7)	45.6 ± 7.7 (6.3 ± 0.7)	45.8 ± 7.5 (6.3 ± 0.7)	0.84

Results are given as *n* (%), mean ± SD or median (range) Missing data were below 5% for all variables

in women monitored by either rtCGM or iCGM are illustrated in Fig. 2a,b. The most substantial differences in mean glucose occurred during the second and early third trimester.

Discussion

In this study, using CGM-derived measures to describe glucose control, we found that mean glucose levels, SD of mean glucose levels, and time spent in and outside the target range (3.5–7.8 mmol/l) during the second and third trimesters were the most important predictors of LGA and neonatal outcomes. The

maternal and neonatal outcomes did not differ between rtCGM users and iCGM users. The glucose patterns were comparable between the two groups throughout pregnancy, except for lower LBGI and less time spent below target in rtCGM users.

To our knowledge, this is the first study to analyse a large clinical dataset of CGM readings during pregnancy in a contemporary real-world setting. It is also the first study to report summary CGM data on the use of Freestyle Libre in pregnancies in women with type 1 diabetes. Not surprisingly, there was a clear trend of improved glucose control with increasing gestational age. The percentage of time spent in target range increased from 50% in the first trimester to 60% in the third

Table 2 Maternal and neonatal outcomes according to glucose monitoring system

Outcome	Total cohort (n = 186)	rtCGM (n = 92)	iCGM (n = 94)	p value
Pre-eclampsia/PIH	34 (18)	15 (16)	19 (20)	0.47
Caesarean section	87 (47)	46 (50)	41 (44)	0.38
Gestational age (weeks)	38 (27–40)	38 (27–40)	38 (29–40)	0.47
Preterm birth (<37 weeks)	52 (28)	24 (26)	28 (30)	0.57
Female infant	87 (47)	48 (52)	39 (41)	0.14
Birthweight, g	3823 ± 711	3812 ± 678	3834 ± 747	0.84
LGA infant	98 (53)	48 (52)	50 (53)	0.89
Macrosomia (>4500 g)	30 (16)	14 (15)	16 (17)	0.74
5 min Apgar score <7	6 (3)	1 (1)	5 (5)	—
Shoulder dystocia	5 (3)	3 (3)	2 (2)	—
Neonatal hypoglycaemia ^a	45 (24)	19 (21)	26 (28)	0.27
NICU admission >24 h	60 (32)	27 (29)	33 (35)	0.40
NCO ^b	83 (45)	37 (40)	46 (49)	0.23

Results are given as *n* (%), mean ± SD or median (range)

^a Defined as plasma glucose < 2.6 mmol/l > 3 h after birth

^b Neonatal composite including ≥ 1 of the following: macrosomia (> 4500 g), shoulder dystocia, neonatal hypoglycaemia or NICU admission > 24 h

Missing data were below 5% for all variables

PIH, pregnancy-induced hypertension

Table 3 Results of the binary logistic regression analysis of variables tested for associations with LGA

Variable	All (n = 186)	LGA (n = 98)	No LGA (n = 88)	Crude data		Adjusted data	
				OR (95% CI)	<i>p</i> value	OR (95% CI)	<i>p</i> value
Trimester 1 (<i>n</i> = 155)							
HbA _{1c} , mmol/mol	52.4 ± 10.5	54.1 ± 1.0	50.4 ± 9.5	1.04 (1.00, 1.07)	0.03	1.04 (1.00, 1.08)	0.02*
HbA _{1c} , %	6.9 ± 1.0	7.1 ± 1.0	6.8 ± 0.9				
Mean glucose, mmol/l	7.8 ± 1.4	7.9 ± 1.3	7.7 ± 1.5	1.12 (0.88, 1.41)	0.35	1.16 (0.91, 1.49)	0.24
SD, mmol/l	3.2 ± 0.9	3.2 ± 0.8	3.2 ± 0.9	1.07 (0.74, 1.55)	0.71	1.09 (0.73, 1.62)	0.67
CV%	40.5 ± 7.2	40.5 ± 7.2	40.6 ± 7.3	1.00 (0.95, 1.04)	0.90	0.99 (0.95, 1.04)	0.77
Time in target, % ^a	50.0 ± 14.1	48.2 ± 13.6	51.9 ± 14.5	0.98 (0.96, 1.00)	0.10	0.98 (0.95, 1.00)	0.07
Time above target, %	43.0 ± 15.5	44.8 ± 14.6	40.9 ± 16.3	1.02 (0.99, 1.04)	0.11	1.02 (1.00, 1.04)	0.07
Time below target, %	7.0 ± 5.0	7.0 ± 5.1	7.2 ± 5.0	0.99 (0.93, 1.06)	0.81	0.98 (0.92, 1.05)	0.60
MAGE	7.7 ± 2.0	7.8 ± 1.8	7.5 ± 2.1	1.08 (0.92, 1.27)	0.37	1.09 (0.92, 1.30)	0.33
HBGI	5.5 ± 3.7	5.6 ± 3.4	5.3 ± 4.1	1.02 (0.94, 1.11)	0.60	1.04 (0.94, 1.13)	0.46
LBGI	2.6 ± 1.6	2.6 ± 1.6	2.7 ± 1.6	0.97 (0.79, 1.18)	0.74	0.94 (0.76, 1.16)	0.54
Trimester 2 (<i>n</i> = 165)							
HbA _{1c} , mmol/mol	45.2 ± 7.9	46.4 ± 7.4	43.7 ± 8.3	1.05 (1.00–1.09)	0.03	1.05 (1.01–1.10)	0.02*
HbA _{1c} , %	6.3 ± 0.7	6.4 ± 0.7	6.1 ± 0.8)				
Mean glucose, mmol/l	7.4 ± 1.2	7.6 ± 1.0	7.1 ± 1.3	1.48 (1.10, 1.98)	<0.01	1.53 (1.12, 2.08)	<0.001*
SD, mmol/l	2.8 ± 0.7	2.9 ± 0.6	2.7 ± 0.7	1.58 (0.98, 2.56)	0.06	1.65 (1.00, 2.74)	<0.05*
CV%	37.7 ± 6.3	37.8 ± 5.9	37.7 ± 6.7	1.00 (0.95, 1.05)	0.92	1.00 (0.95, 1.06)	0.93
Time in target, % ^a	54.7 ± 13.7	51.8 ± 12.3	57.9 ± 14.4	0.96 (0.94, 0.99)	<0.01	0.96 (0.94, 0.99)	<0.01*
Time above target, %	38.1 ± 14.9	41.9 ± 12.8	34.0 ± 15.9	1.04 (1.02, 1.06)	<0.001	1.04 (1.02, 1.07)	<0.001*
Time below target, %	7.2 ± 5.1	6.4 ± 4.5	8.0 ± 5.7	0.94 (0.88, 0.99)	0.04	0.93 (0.87, 0.99)	0.02*
MAGE	6.8 ± 1.5	7.0 ± 1.4	6.6 ± 1.6	1.21 (0.98, 1.48)	0.07	1.22 (0.98, 1.52)	0.06
HBGI	4.0 ± 2.9	4.4 ± 2.4	3.6 ± 3.3	1.11 (0.98, 1.24)	0.08	1.12 (0.99, 1.26)	0.07
LBGI	2.7 ± 1.6	2.4 ± 1.4	3.0 ± 1.8	0.80 (0.66, 0.97)	0.02	0.77 (0.62, 0.94)	0.01*
Trimester 3 (<i>n</i> = 167)							
HbA _{1c} , mmol/mol	45.7 ± 7.6	47.2 ± 6.7	44.0 ± 8.2	1.06 (1.02, 1.11)	<0.01	1.06 (1.02, 1.11)	<0.01*
HbA _{1c} , %	6.3 ± 0.7	6.5 ± 0.6	6.2 ± 0.8				
Mean glucose, mmol/l	7.1 ± 1.1	7.3 ± 1.1	6.8 ± 1.1	1.57 (1.13, 2.16)	<0.01	1.57 (1.12, 2.19)	<0.001*
SD, mmol/l	2.6 ± 0.6	2.6 ± 0.6	2.5 ± 0.6	1.58 (0.93, 2.68)	0.08	1.60 (0.92, 2.77)	0.09
CV%	36.0 ± 5.8	35.9 ± 5.5	36.1 ± 6.2	0.99 (0.94, 1.05)	0.83	0.99 (0.94, 1.05)	0.84
Time in target, % ^a	59.8 ± 13.3	57.6 ± 12.8	62.2 ± 13.4	0.97 (0.95, 1.00)	0.02	0.97 (0.95, 1.00)	0.04*
Time above target, %	33.7 ± 14.8	37.0 ± 13.5	30.2 ± 15.3	1.03 (1.01, 1.06)	<0.01	1.03 (1.01, 1.06)	<0.01*
Time below target, %	6.5 ± 5.6	5.4 ± 4.4	7.6 ± 6.4	0.93 (0.87, 0.98)	<0.01	0.92 (0.86, 0.98)	<0.01*
MAGE	6.2 ± 1.4	6.3 ± 1.4	6.0 ± 1.5	1.16 (0.93, 1.44)	0.18	1.16 (0.92, 1.45)	0.20
HBGI	3.3 ± 2.5	3.6 ± 2.7	2.9 ± 2.3	1.15 (1.00, 1.34)	0.04	1.15 (1.00, 1.34)	0.05
LBGI	2.6 ± 1.7	2.3 ± 1.4	2.9 ± 1.9	0.78 (0.63, 0.94)	<0.01	0.76 (0.61, 0.94)	<0.01*

Results are given as mean ± SD

^a Defined as glucose level 3.5–7.8 mmol/l*A significant association ($p < 0.05$) in a hierarchical binary logistic regression analysis with adjustment for age, smoking, BMI and CGM device

trimester. These figures are somewhat higher than reported by Murphy et al from the first randomised controlled trial of intermittent use of CGM in pregnancy [30]. In their cohort of type 1 diabetes women, the corresponding proportions were 43% and 56%, respectively. The time spent above target in late pregnancy was similar to ours (33% vs 34%), whereas the time spent below target was higher (13% vs 7%). A more

narrow definition of target range (3.9–7.8 mmol/l) may account for some of these differences. Although CGM users in the CONCEPTT study spent substantially higher time in target (68%) and less time below target (3%) compared with previous studies, the proportion of time spent above target remained high (27%) [21]. These results indicate that additional strategies might be required to optimise glucose control




Fig. 2 (a) Mean \pm SEM of interstitial glucose levels during pregnancy in women with (white) and without (black) fetal overgrowth (LGA). (b) Mean \pm SEM of interstitial glucose levels during pregnancy in women with (white) and without (black) short-term neonatal complications

in pregnancies in women with type 1 diabetes—in particular to minimise postprandial glucose excursions. Closed-loop therapy in pregnancy has shown promise in reducing time in hypoglycaemia, but for now, no effect has been demonstrated on time in hyperglycaemia [31, 32].

Interestingly, we found no differences in maternal and neonatal outcomes between women using iCGM and rtCGM, which may support the non-inferior use of iCGM in pregnancy. However, the observational design of the study means that firm conclusions cannot be drawn. Of note, women using rtCGM more often used insulin pumps and had a longer duration of diabetes. Compared with iCGM users, they also spent less time in hypoglycaemia throughout pregnancy. Real-world data from Sweden suggest that insulin pump users have higher HbA_{1c} levels when starting pump therapy

compared with non-pump users and are more likely to be women and aged 20–30 years [33]. Although glycaemic control measured by HbA_{1c} was similar between rtCGM users and iCGM users at baseline, this does not preclude previous differences at the time of pump therapy initiation. These circumstances mean it is likely that glycaemic disturbance in rtCGM users was more severe and these women were in greater need of a CGM system with an alarm function.

Poor glycaemic control assessed by HbA_{1c} has long been associated with accelerated fetal growth, particularly during the second and third trimesters [2, 12, 34–36]. Accordingly, in this study, HbA_{1c} was an important glucose variable, predicting LGA and neonatal outcomes—in particular, third trimester HbA_{1c}. In our cohort, 36% of the women reached the target HbA_{1c} level of <48 mmol/mol (6.5%) in early pregnancy and 70% in the second and the third trimesters. These results are more favourable than those recently reported from a nationwide study in the UK, in which 16% reached the corresponding HbA_{1c} target in early pregnancy and 40% reached it after 24 weeks of gestation [15]. Nevertheless, the 53% prevalence of LGA infants is high and confirms previous findings that a substantial proportion of pregnancies among women with type 1 diabetes result in delivery of LGA infants [1–3, 21]. Our results are not directly comparable with most other studies because of differences in the definition of LGA. Using the same definition of LGA as we did (birthweight >2 SD of the ultrasound-based intrauterine reference curve), Law et al reported an LGA prevalence of 45.6% in their subgroup of 68 Danish women with pregestational diabetes randomised to intermittent use of CGM during pregnancy [18]. Taking into account that 21% of the women had type 2 diabetes, their reported LGA prevalence can be considered similar to ours. We have previously reported an LGA prevalence of 23% in pregnancies among women with type 2 diabetes, as opposed to 50% among those with type 1 diabetes [36]. Tightened glucose control early in pregnancy might possibly have changed our results. It has been argued that glycaemic control needs to be optimised very early in pregnancy to prevent fetal overgrowth as a consequence of early establishment of fetal hyperinsulinaemia, a driver of the fetal glucose steal phenomenon [37].

Given that HbA_{1c} provides a retrospective measure of average glucose levels, it is less likely to detect short-term variation in glucose levels that might be relevant in the development of LGA. However, no significant associations were found between any of the CGM measurements and LGA in the first trimester. Our data support findings from previous studies suggesting that relatively high glucose levels during the second and third trimester are predictive of LGA and adverse neonatal outcomes [12, 16, 18]. Furthermore, the SD of mean glucose in the second and third trimesters were significantly associated with LGA and NCO, respectively. Several studies have demonstrated an association between various CGM-derived measures of glucose variability and birthweight [18–20, 38]. In line with this, women in

the CGM group of the CONCEPTT study had reduced SD and lower MAGE, indicating less glycaemic variability [21]. In contrast, Mulla et al did not observe any trimester-specific associations between glycaemic variability (CV%) and birthweight in a retrospective cohort study of 41 women with type 1 diabetes using real-time CGM for up to 30 consecutive days in each trimester [39]. Some of these discrepancies between studies may have arisen from differences in study design and from the use of different surrogate measures of glycaemic variability. It is important to note that the previous studies—except CONCEPTT—were based on intermittent use of CGM.

Our study should be interpreted in the context of its limitations and strengths. First, this was a clinically based observational study, which precludes us from making causal inferences. Second, the women used two different types of CGM, either rtCGM or iCGM, which may have affected the quality of glycaemic variability measurements. Third, the women were predominantly of European descent which may possibly limit the generalisability to other populations. Fourth, we followed the recently published data on use of CGM outside of pregnancy and required that there was a minimum of 14 consecutive days of data with at least 80% coverage for inclusion [22]. Considering the rapidly changing phases of insulin demands during pregnancy, 7-day profiles may better reflect the dynamic changes during pregnancy. Strengths of the study include the access to a large number of CGM readings based on optimal reports from CGM devices worn on a near-daily basis. From a clinical point of view, the observational design of the study—considering real-world data from all women using a CGM device during pregnancy—is a strength. Furthermore, information on important confounders, such as age, BMI and smoking, was available and controlled for in the logistic regression models [40].

In the present study, we sought to gain local experience of wearing CGM during pregnancy. Despite the use of CGM throughout pregnancy, the day-to-day glucose control was not optimal and the incidence of LGA remained high. There is a need for greater support from the diabetes team during pregnancy for technical assistance and intensified focus on postprandial hyperglycaemia, including dietary advice/carbohydrate counting and a supported active approach to prandial insulin adjustments. Because of ease of use and low cost, the iCGM system has become increasingly popular in Sweden among both individuals with diabetes and caregivers. The system has been considered safe and accurate for use in pregnant women with diabetes [41, 42]. It is our clinical experience that many women prefer to use iCGM rather than rtCGM in pregnancy. Further randomised trials to assess the impact of iCGM vs rtCGM on glucose control and neonatal outcomes in pregnancy are warranted.

Acknowledgements We are indebted to C. Cato of The Parker Research Institute for taking on the challenge of data management and to P-E Isberg of Lund University for statistical support. Finally, we are grateful to all the women who participated in the study.

Data availability Data are available on request from the authors.

Funding The study was funded by a research grant from Region Skåne, Sweden, and The Oak Foundation.

Duality of interest The authors declare that there is no duality of interest associated with this manuscript.

Contribution statement All the authors took part in the design of the study and approved the final version of the manuscript to be published. KK and KB researched data and wrote the manuscript. KKj and LK researched data and reviewed/edited the manuscript. LEÖ, VS, AD, AE, FKK, NW, AK and NS contributed to the discussion and reviewed the manuscript. KK is the guarantor of this work.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

- Persson M, Pasupathy D, Hanson U, Norman M (2011) Birth size distribution in 3,705 infants born to mothers with type 1 diabetes: a population-based study. *Diabetes Care* 34(5):1145–1149. <https://doi.org/10.2337/dc10-2406>
- Evers IM, de Valk HW, Mol BW, ter Braak EW, Visser GH (2002) Macrosomia despite good glycaemic control in type I diabetic pregnancy; results of a nationwide study in the Netherlands. *Diabetologia* 45:1484–1489
- Jensen DM, Damm P, Moelsted-Pedersen L et al (2004) Outcomes in type 1 diabetic pregnancies: a nationwide, population-based study. *Diabetes Care* 27(12):2819–2823. <https://doi.org/10.2337/diacare.27.12.2819>
- Persson M, Pasupathy D, Hanson U, Norman M (2012) Disproportionate body composition and perinatal outcome in large-for-gestational-age infants to mothers with type 1 diabetes. *BJOG* 119(5):565–572. <https://doi.org/10.1111/j.1471-0528.2012.03277.x>
- Clausen TD, Mathiesen ER, Hansen T et al (2008) High prevalence of type 2 diabetes and pre-diabetes in adult offspring of women with gestational diabetes mellitus or type 1 diabetes: the role of intrauterine hyperglycemia. *Diabetes Care* 31(2):340–346. <https://doi.org/10.2337/dc07-1596>
- Hillier TA, Pedula KL, Schmidt MM, Mullen JA, Charles MA, Pettitt DJ (2007) Childhood obesity and metabolic imprinting: the ongoing effects of maternal hyperglycemia. *Diabetes Care* 30(9):2287–2292. <https://doi.org/10.2337/dc06-2361>
- Manderson JG, Mullan B, Patterson CC, Hadden DR, Traub AI, McCance DR (2002) Cardiovascular and metabolic abnormalities in the offspring of diabetic pregnancy. *Diabetologia* 45(7):991–996. <https://doi.org/10.1007/s00125-002-0865-y>
- Rijpert M, Evers IM, de Vroede MA, de Valk HW, Heijnen CJ, Visser GH (2009) Risk factors for childhood overweight in offspring of type 1 diabetic women with adequate glycemic control during pregnancy: nationwide follow-up study in the Netherlands. *Diabetes Care* 32(11):2099–2104. <https://doi.org/10.2337/dc09-0652>
- Pedersen J (1954) Weight and length at birth of infants of diabetic mothers. *Acta Endocrinol* 16(4):330–342. <https://doi.org/10.1530/acta.0.0160330>
- Jovanovic-Peterson L, Peterson CM, Reed GF et al (1991) Maternal postprandial glucose levels and infant birth weight: the Diabetes in

- Early Pregnancy Study. The National Institute of Child Health and Human Development—Diabetes in Early Pregnancy Study. *Am J Obstet Gynecol* 164:103–111
11. Herranz L, Pallardo LF, Hillman N, Martin-Vaquero P, Villarroel A, Fernandez A (2007) Maternal third trimester hyperglycaemic excursions predict large-for-gestational-age infants in type 1 diabetic pregnancy. *Diabetes Res Clin Pract* 75(1):42–46. <https://doi.org/10.1016/j.diabres.2006.05.019>
 12. Kerssen A, de Valk HW, Visser GH (2007) Increased second trimester maternal glucose levels are related to extremely large-for-gestational-age infants in women with type 1 diabetes. *Diabetes Care* 30(5):1069–1074. <https://doi.org/10.2337/dc06-1985>
 13. Garcia-Patterson A, Gich I, Amini SB, Catalano PM, de Leiva A, Corcoy R (2010) Insulin requirements throughout pregnancy in women with type 1 diabetes mellitus: three changes of direction. *Diabetologia* 53(3):446–451. <https://doi.org/10.1007/s00125-009-1633-z>
 14. Goudie RJ, Lunn D, Hovorka R, Murphy HR (2014) Pharmacokinetics of insulin aspart in pregnant women with type 1 diabetes: every day is different. *Diabetes Care* 37(6):e121–e122. <https://doi.org/10.2337/dc13-2535>
 15. Murphy HR, Bell R, Cartwright C et al (2017) Improved pregnancy outcomes in women with type 1 and type 2 diabetes but substantial clinic-to-clinic variations: a prospective nationwide study. *Diabetologia* 60(9):1668–1677. <https://doi.org/10.1007/s00125-017-4314-3>
 16. Murphy HR, Rayman G, Lewis K et al (2008) Effectiveness of continuous glucose monitoring in pregnant women with diabetes: randomised clinical trial. *BMJ* 337:a1680. <https://doi.org/10.1136/bmj.a1680>
 17. Secher AL, Ringholm L, Andersen HU, Damm P, Mathiesen ER (2013) The effect of real-time continuous glucose monitoring in pregnant women with diabetes: a randomized controlled trial. *Diabetes Care* 36(7):1877–1883. <https://doi.org/10.2337/dc12-2360>
 18. Law GR, Ellison GT, Secher AL et al (2015) Analysis of continuous glucose monitoring in pregnant women with diabetes: distinct temporal patterns of glucose associated with large-for-gestational-age infants. *Diabetes Care* 38(7):1319–1325. <https://doi.org/10.2337/dc15-0070>
 19. Gupta R, Khoury J, Altaye M, Dolan L, Szczesniak RD (2017) Glycemic excursions in type 1 diabetes in pregnancy: a semiparametric statistical approach to identify sensitive time points during gestation. *J Diabetes Res* 2017:2852913
 20. McGrath RT, Glastras SJ, Seeho SK, Scott ES, Fulcher GR, Hocking SL (2017) Association between glycemic variability, HbA_{1c}, and large-for-gestational-age neonates in women with type 1 diabetes. *Diabetes Care* 40(8):e98–e100. <https://doi.org/10.2337/dc17-0626>
 21. Feig DS, Donovan LE, Corcoy R et al (2017) Continuous glucose monitoring in pregnant women with type 1 diabetes (CONCEPTT): a multicentre international randomised controlled trial. *Lancet* 390(10110):2347–2359. [https://doi.org/10.1016/S0140-6736\(17\)32400-5](https://doi.org/10.1016/S0140-6736(17)32400-5)
 22. Danne T, Nimri R, Battelino T et al (2017) International consensus on use of continuous glucose monitoring. *Diabetes Care* 40(12):1631–1640. <https://doi.org/10.2337/dc17-1600>
 23. Service FJ, O'Brien PC, Rizza RA (1987) Measurements of glucose control. *Diabetes Care* 10(2):225–237. <https://doi.org/10.2337/diacare.10.2.225>
 24. Kovatchev BP, Cox DJ, Gonder-Frederick LA, Clarke W (1997) Symmetrization of the blood glucose measurement scale and its applications. *Diabetes Care* 20(11):1655–1658. <https://doi.org/10.2337/diacare.20.11.1655>
 25. Baghurst PA (2011) Calculating the mean amplitude of glycemic excursion from continuous glucose monitoring data: an automated algorithm. *Diabetes Technol Ther* 13(3):296–302. <https://doi.org/10.1089/dia.2010.0090>
 26. Baghurst PA, Rodbard D, Cameron FJ (2010) The minimum frequency of glucose measurements from which glycemic variation can be consistently assessed. *J Diabetes Sci Technol* 4(6):1382–1385. <https://doi.org/10.1177/193229681000400612>
 27. Fabris C, Patek SD, Breton MD (2015) Are risk indices derived from CGM interchangeable with SMBG-based indices? *J Diabetes Sci Technol* 10:50–59
 28. Marsal K, Persson PH, Larsen T, Lilja H, Selbing A, Sultan B (1996) Intrauterine growth curves based on ultrasonically estimated foetal weights. *Acta Paediatr* 85(7):843–848. <https://doi.org/10.1111/j.1651-2227.1996.tb14164.x>
 29. Ananth CV, Schisterman EF (2017) Confounding, causality, and confusion: the role of intermediate variables in interpreting observational studies in obstetrics. *Am J Obstet Gynecol* 217(2):167–175. <https://doi.org/10.1016/j.ajog.2017.04.016>
 30. Murphy HR, Rayman G, Duffield K et al (2007) Changes in the glycemic profiles of women with type 1 and type 2 diabetes during pregnancy. *Diabetes Care* 30(11):2785–2791. <https://doi.org/10.2337/dc07-0500>
 31. Stewart ZA, Wilinska ME, Hartnell S et al (2016) Closed-loop insulin delivery during pregnancy in women with type 1 diabetes. *NEJM* 375(7):644–654. <https://doi.org/10.1056/NEJMoa1602494>
 32. Stewart ZA, Wilinska ME, Hartnell S et al (2018) Day-and-night closed-loop insulin delivery in a broad population of pregnant women with type 1 diabetes: a randomized controlled crossover trial. *Diabetes Care* 41(7):1391–1399. <https://doi.org/10.2337/dc17-2534>
 33. Carlsson BM, Andersson PN, Alnervik J, Carstensen J, Lind M (2012) Availability of insulin pump therapy in clinical practice. *Diabet Med* 29(8):1055–1059. <https://doi.org/10.1111/j.1464-5491.2011.03517.x>
 34. Glinianaia SV, Tennant PW, Bilous RW, Rankin J, Bell R (2012) HbA_{1c} and birthweight in women with pre-conception type 1 and type 2 diabetes: a population-based cohort study. *Diabetologia* 55(12):3193–3203. <https://doi.org/10.1007/s00125-012-2721-z>
 35. Murphy HR, Steel SA, Roland JM et al (2011) Obstetric and perinatal outcomes in pregnancies complicated by type 1 and type 2 diabetes: influences of glycaemic control, obesity and social disadvantage. *Diabet Med* 28(9):1060–1067. <https://doi.org/10.1111/j.1464-5491.2011.03333.x>
 36. Ladfors L, Shaat N, Wiberg N, Katarasou A, Berntorp K, Kristensen K (2017) Fetal overgrowth in women with type 1 and type 2 diabetes mellitus. *PLoS One* 12(11):e0187917. <https://doi.org/10.1371/journal.pone.0187917>
 37. Desoye G, Nolan CJ (2016) The fetal glucose steal: an underappreciated phenomenon in diabetic pregnancy. *Diabetologia* 59(6):1089–1094. <https://doi.org/10.1007/s00125-016-3931-6>
 38. Dalfrà MG, Sartore G, Di Cianni G et al (2011) Glucose variability in diabetic pregnancy. *Diabetes Technol Ther* 13(8):853–859. <https://doi.org/10.1089/dia.2010.0145>
 39. Mulla BM, Noor N, James-Todd T et al (2018) Continuous glucose monitoring, glycemic variability, and excessive fetal growth in pregnancies complicated by type 1 diabetes. *Diabetes Technol Ther* 20(6):413–419. <https://doi.org/10.1089/dia.2017.0443>

40. Lindell G, Marsal K, Kallen K (2012) Impact of maternal characteristics on fetal growth in the third trimester: a population-based study. *Ultrasound Obstet Gynecol* 40(6):680–687. <https://doi.org/10.1002/uog.11125>
41. Scott EM, Bilous RW, Kautzky-Willer A (2018) Accuracy, user acceptability, and safety evaluation for the freestyle libre flash glucose monitoring system when used by pregnant women with diabetes. *Diabetes Technol Ther* 20(3):180–188. <https://doi.org/10.1089/dia.2017.0386>
42. Leelarathna L, Wilmot EG (2018) Flash forward: a review of flash glucose monitoring. *Diabet Med* 35(4):472–482. <https://doi.org/10.1111/dme.13584>

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.